Literature DB >> 29374974

Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.

Rebecca Kahn1, Matt Hitchings1, Steven Bellan2, Marc Lipsitch1,3.   

Abstract

Background/aims Network structure and individuals' level of exposure to a pathogen can impact results from efficacy evaluation studies of interventions against infectious diseases. Heterogeneity in infection risk can cause randomized groups to increasingly differ as a trial progresses and as more high-risk individuals become infected (described in prior work as the "frailty" phenomenon). Here, we show the impact this phenomenon can have on an individually randomized trial of a leaky vaccine in which all participants are exchangeable a priori. Methods We model a vaccine trial by generating a network of individuals grouped into communities, which are connected to a larger main population. We then simulate an epidemic, deterministically and with time-varying transmission rates in the main population and stochastically in the communities. The disease natural history follows a susceptible-exposed-infectious-recovered model. Simulation results are used to estimate vaccine efficacy [Formula: see text] with a Cox proportional hazards model. Results We find downward bias in [Formula: see text] associated with low connectivity between communities in the study population and high force of infection, even when all participants in the trial are exchangeable at the time of randomization. This phenomenon arises because the stochastic dynamics in such a setting randomly lead to community-level variation in the force of infection. Stratifying a Cox model by community alleviates this bias with no loss of power. Conclusion Understanding and accounting for the impact of heterogeneous hazard rates can allow for more accurate estimates of [Formula: see text] in epidemic settings.

Entities:  

Keywords:  Vaccine trial; epidemics; frailty; heterogeneous hazards; infectious disease

Mesh:

Substances:

Year:  2018        PMID: 29374974      PMCID: PMC5891371          DOI: 10.1177/1740774517752671

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  14 in total

1.  Estimability and interpretation of vaccine efficacy using frailty mixing models.

Authors:  M E Halloran; I M Longini; C J Struchiner
Journal:  Am J Epidemiol       Date:  1996-07-01       Impact factor: 4.897

Review 2.  Direct and indirect effects in vaccine efficacy and effectiveness.

Authors:  M E Halloran; M Haber; I M Longini; C J Struchiner
Journal:  Am J Epidemiol       Date:  1991-02-15       Impact factor: 4.897

3.  Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies.

Authors:  P G Smith; L C Rodrigues; P E Fine
Journal:  Int J Epidemiol       Date:  1984-03       Impact factor: 7.196

4.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Authors:  Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville
Journal:  N Engl J Med       Date:  2015-07-27       Impact factor: 91.245

5.  Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.

Authors:  Firdausi Qadri; Thomas F Wierzba; Mohammad Ali; Fahima Chowdhury; Ashraful I Khan; Amit Saha; Iqbal A Khan; Muhammad Asaduzzaman; Afroza Akter; Arifuzzaman Khan; Yasmin A Begum; Taufiqur R Bhuiyan; Farhana Khanam; Mohiul I Chowdhury; Taufiqul Islam; Atique I Chowdhury; Anisur Rahman; Shah A Siddique; Young A You; Deok R Kim; Ashraf U Siddik; Nirod C Saha; Alamgir Kabir; Alejandro Cravioto; Sachin N Desai; Ajit P Singh; John D Clemens
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

6.  Interpretation and estimation of vaccine efficacy under heterogeneity.

Authors:  M E Halloran; M Haber; I M Longini
Journal:  Am J Epidemiol       Date:  1992-08-01       Impact factor: 4.897

7.  Estimating the per-exposure effect of infectious disease interventions.

Authors:  Justin J O'Hagan; Marc Lipsitch; Miguel A Hernán
Journal:  Epidemiology       Date:  2014-01       Impact factor: 4.822

8.  Incorporating Contact Network Structure in Cluster Randomized Trials.

Authors:  Patrick C Staples; Elizabeth L Ogburn; Jukka-Pekka Onnela
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

9.  Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis.

Authors:  Paul T Edlefsen
Journal:  Comput Math Methods Med       Date:  2014-05-07       Impact factor: 2.238

10.  Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections.

Authors:  Bruce Aylward; Philippe Barboza; Luke Bawo; Eric Bertherat; Pepe Bilivogui; Isobel Blake; Rick Brennan; Sylvie Briand; Jethro Magwati Chakauya; Kennedy Chitala; Roland M Conteh; Anne Cori; Alice Croisier; Jean-Marie Dangou; Boubacar Diallo; Christl A Donnelly; Christopher Dye; Tim Eckmanns; Neil M Ferguson; Pierre Formenty; Caroline Fuhrer; Keiji Fukuda; Tini Garske; Alex Gasasira; Stephen Gbanyan; Peter Graaff; Emmanuel Heleze; Amara Jambai; Thibaut Jombart; Francis Kasolo; Albert Mbule Kadiobo; Sakoba Keita; Daniel Kertesz; Moussa Koné; Chris Lane; Jered Markoff; Moses Massaquoi; Harriet Mills; John Mike Mulba; Emmanuel Musa; Joel Myhre; Abdusalam Nasidi; Eric Nilles; Pierre Nouvellet; Deo Nshimirimana; Isabelle Nuttall; Tolbert Nyenswah; Olushayo Olu; Scott Pendergast; William Perea; Jonathan Polonsky; Steven Riley; Olivier Ronveaux; Keita Sakoba; Ravi Santhana Gopala Krishnan; Mikiko Senga; Faisal Shuaib; Maria D Van Kerkhove; Rui Vaz; Niluka Wijekoon Kannangarage; Zabulon Yoti
Journal:  N Engl J Med       Date:  2014-09-22       Impact factor: 91.245

View more
  4 in total

1.  Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials.

Authors:  Matt D T Hitchings; Marc Lipsitch; Rui Wang; Steven E Bellan
Journal:  Am J Epidemiol       Date:  2018-08-01       Impact factor: 4.897

2.  Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.

Authors:  Rebecca Kahn; Matt Hitchings; Rui Wang; Steven E Bellan; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2019-02-01       Impact factor: 4.897

3.  Potential biases arising from epidemic dynamics in observational seroprotection studies.

Authors:  Rebecca Kahn; Lee Kennedy-Shaffer; Yonatan H Grad; James M Robins; Marc Lipsitch
Journal:  medRxiv       Date:  2020-05-06

4.  Potential Biases Arising From Epidemic Dynamics in Observational Seroprotection Studies.

Authors:  Rebecca Kahn; Lee Kennedy-Shaffer; Yonatan H Grad; James M Robins; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2021-02-01       Impact factor: 4.897

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.